Retatrutide: The Next Evolution in Medical Weight Loss?
A new triple-action medication is coming, but it is not available in clinics yet.
Retatrutide is one of the most talked-about medications in the future of medical weight loss. It is being developed by Eli Lilly as a once-weekly injectable medication that works on three hormone receptors: GLP-1, GIP, and glucagon. Because of this, it is often called a “triple agonist.” Semaglutide works mainly through GLP-1. Tirzepatide works through GLP-1 and GIP. Retatrutide adds glucagon receptor activity, which may give it a stronger effect on appetite regulation, energy balance, fat loss, and cardiometabolic health.[1-3]
Retatrutide is still investigational. It is not currently FDA approved and is not legally available for routine prescribing outside clinical trials.[1] At Modern Wellness, we are watching Retatrutide closely because the clinical study results are promising. However, we believe patients should be educated clearly: Retatrutide is not something you should buy from the internet, social media, “research peptide” sellers, overseas suppliers, or gray-market sources.
If someone is selling “Retatrutide” today outside a legitimate clinical trial, there is no real medical accountability, no FDA approval, no verified dosing, and no guarantee that the product is sterile, pure, correctly labeled, or safe for injection.
How Retatrutide Compares to Semaglutide and Tirzepatide
Semaglutide, best known by brand names such as Wegovy and Ozempic, is a GLP-1 receptor agonist. In the STEP 1 trial, semaglutide 2.4 mg produced an average weight reduction of 14.9% at 68 weeks compared with 2.4% with placebo.[4]
Tirzepatide, best known by brand names such as Zepbound and Mounjaro, works on both GIP and GLP-1 receptors. In the SURMOUNT-1 trial, tirzepatide produced average weight loss of 15.0%, 19.5%, and 20.9% at 72 weeks depending on dose, compared with 3.1% with placebo.[5]
Retatrutide is designed to go one step further by activating GIP, GLP-1, and glucagon receptors. In its Phase 2 obesity study, Retatrutide produced up to 17.5% mean weight reduction at 24 weeks and up to 24.2% mean weight reduction at 48 weeks.[2] In Lilly’s first successful Phase 3 obesity-related trial, TRIUMPH-4, adults with obesity or overweight and knee osteoarthritis taking Retatrutide 12 mg lost an average of 28.7% of body weight at 68 weeks.[6]
What the Retatrutide Studies Are Showing
The Retatrutide data are exciting because the weight loss appears to be very strong, and in some studies, patients had not yet clearly plateaued. In a Phase 2 trial in people with type 2 diabetes, Retatrutide produced clinically meaningful improvements in blood sugar control and strong reductions in body weight over 36 weeks.[3]
In Lilly’s Phase 3 TRANSCEND-T2D-1 study for type 2 diabetes, Retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks. Participants taking 12 mg lost an average of 36.6 pounds, or 16.8% of body weight. Lilly also reported that weight loss had not plateaued through 40 weeks in that study.[7]
In TRIUMPH-4, the study population included adults with obesity or overweight and knee osteoarthritis. Retatrutide 12 mg produced an average 28.7% weight loss at 68 weeks and also improved knee pain and physical function measures. The most common reported side effects were similar to other incretin medications, including nausea, diarrhea, constipation, vomiting, and decreased appetite. Lilly also reported dysesthesia, an abnormal skin sensation, more often in Retatrutide-treated patients than placebo.[6]
This does not mean Retatrutide is automatically “better” for every person. A medication that produces stronger weight loss may also require more careful medical oversight, slower dose escalation, better nutrition planning, attention to hydration, and stronger muscle-preservation strategies. The best weight-loss medication is not just the one that moves the scale fastest. It is the one that helps the patient lose fat, protect muscle, improve metabolic health, and maintain results safely.
When Will Retatrutide Be Available in the Clinic?
As of 2026, Retatrutide is not FDA approved and is not available for routine prescribing. Lilly states that Retatrutide is being studied in Phase 3 clinical trials for obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.[1]
A realistic expectation is that Retatrutide may reach the clinic only after the remaining Phase 3 data are completed, submitted, reviewed, and approved by the FDA. The FDA’s standard review goal for a new drug application is generally 10 months, while priority review has a 6-month goal, but those timelines only begin after a complete application is accepted.[8]
Because of that, any exact launch date would be speculation. If future trial results remain positive and the FDA review process goes smoothly, Retatrutide could possibly become available after regulatory review, but there is no guaranteed approval date, no confirmed launch date, and no official clinic availability date at this time.
What Might Retatrutide Cost?
No official Retatrutide price has been announced because it is not yet FDA approved. Pricing will depend on FDA approval, indication, manufacturing, insurance coverage, savings programs, direct-pay options, and market competition.
Existing GLP-1 and GIP/GLP-1 medications show how variable pricing can be. Current branded obesity medications can be expensive, and patient cost often depends on insurance coverage, manufacturer programs, pharmacy access, and whether the medication is prescribed under a covered diagnosis.[9]
Retatrutide could be priced similarly to current branded obesity medications, or it could be priced higher because it is a newer triple-agonist medication. It is also possible that manufacturer savings programs, insurance negotiations, or direct-pay programs could change what patients actually pay. Until Lilly announces official pricing, any specific monthly price should be treated as an estimate, not a fact.
Why You Should Avoid Gray-Market Retatrutide
The most important safety message is simple: do not buy Retatrutide from the gray market. That includes “research use only” websites, social media sellers, overseas peptide shops, private forums, or anyone claiming they can sell you Retatrutide before FDA approval.
Many gray-market peptides are sold as powders with no reliable chain of custody, no medical prescription, no verified sterility, no verified dose, no proper patient screening, and no medical follow-up. Even when a label claims “99% pure,” that does not guarantee the product is sterile, endotoxin-free, correctly dosed, free of harmful residual solvents, or safe for injection.
One major concern with synthetic peptides is trifluoroacetic acid, often abbreviated TFA. TFA is commonly used in peptide synthesis and purification. Residual trifluoroacetate can remain in peptide preparations, and published analytical literature notes that TFA removal should be reliably measured in products intended for preclinical or clinical use because TFA is toxic and undesirable in these settings.[10] In legitimate pharmaceutical manufacturing, purification, salt exchange, analytical testing, sterility, potency, and endotoxin controls matter.
Another concern is endotoxin contamination. Endotoxins come from gram-negative bacteria and are important pharmaceutical contaminants because they can trigger pyrogenic reactions. FDA guidance discusses the importance of bacterial endotoxin and pyrogen testing for drug and device products, especially products that enter the body through injection.[11,12] Endotoxin contamination can come from water, raw materials, packaging components, or processing equipment, and it can be difficult to remove once present.
This is why “cheap” peptides can become very expensive very quickly. An improperly made injectable product can expose a patient to infection risk, inflammatory reactions, dosing errors, immune reactions, contaminants, and unknown impurities. Retatrutide should only be considered when it is FDA approved and prescribed through a legitimate medical pathway, or if a patient is enrolled in an appropriate clinical trial.
The Modern Wellness Approach: Medical Weight Loss With Muscle Protection
At Modern Wellness, we do not believe medical weight loss should be reduced to “take a shot and eat less.” That approach can lead to under-eating, fatigue, nutrient deficiencies, loss of muscle, and eventual weight regain. Our goal is fat loss with metabolic improvement, muscle preservation, and long-term success.
When clinically appropriate and legally available, Modern Wellness uses Tirzepatide through a reputable, state-licensed 503A compounding pharmacy source. Patients should understand that compounded medications are not FDA-approved drugs, and the FDA states that compounded drugs should generally be used when a patient’s medical needs cannot be met by an FDA-approved medication.[13,14] This is why source, accountability, prescription oversight, sterility, and medical supervision matter.
Our Modern Wellness program may also pair Tirzepatide care with separate supportive therapies such as NAD+ and lipotropic injections when appropriate. NAD+ support is often used in wellness medicine to support cellular energy and vitality. Lipotropic injections may include nutrients commonly used to support fat metabolism and liver-related pathways. These are not magic shots and they do not replace nutrition, protein, resistance training, sleep, hydration, or medical oversight. Used correctly, however, they can be part of a more complete program for patients who need additional support while losing weight.
Why Sarcopenia Matters During GLP-1 Weight Loss
Sarcopenia means loss of muscle mass, strength, and function. It becomes more common with aging, inactivity, hormonal changes, poor protein intake, and rapid weight loss. For men and women over 40, and especially over 50, preserving muscle is one of the most important parts of a successful weight-loss plan.
GLP-1-based medications can produce excellent fat loss, but body composition still matters. In semaglutide body-composition research, total fat mass and visceral fat mass decreased, while lean mass also decreased, although the proportion of lean mass relative to total body mass improved.[15] Tirzepatide body-composition analyses have also shown large reductions in fat mass with some reduction in lean mass, which is expected during major weight loss.[16]
At Modern Wellness, we build the program around protecting muscle. That means adequate protein, strength training, resistance-based movement, hydration, minerals, follow-up visits, and realistic dose escalation. For many patients, the goal is not just to weigh less. The goal is to become metabolically healthier, stronger, more energetic, and more capable in daily life.
Our Weight-Loss Philosophy
Retatrutide may become an important medication in the future of obesity medicine. The early studies are promising, and the Phase 3 data so far suggest that triple-agonist therapy may offer a new level of weight-loss potential.[2,6,7] But right now, Retatrutide is not an approved clinic medication.
Today, Modern Wellness focuses on what is available, appropriate, and medically supervised: Tirzepatide-based weight-loss care, supportive NAD+ and lipotropic options, lifestyle coaching, sarcopenia prevention, and a whole-person plan designed to help patients lose fat while protecting their strength, energy, and long-term health.
Call Modern Wellness
If you are interested in medical weight loss, GLP-1 therapy, Tirzepatide, NAD+, lipotropic injections, or a muscle-preserving weight-loss strategy, Modern Wellness can help you build a plan that fits your body, your goals, and your long-term health.
Modern Wellness
Medical Weight Loss • Tirzepatide Support • NAD+ • Lipotropic Injections • Muscle Preservation
Call today to schedule your consultation.
References
Eli Lilly and Company. What are the preliminary results with retatrutide from TRIUMPH-4 in participants with obesity or overweight and osteoarthritis? Lilly Medical. Accessed May 6, 2026.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Published December 11, 2025. Accessed May 6, 2026.
Eli Lilly and Company. Lilly’s triple agonist retatrutide demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. Published March 19, 2026. Accessed May 6, 2026.
US Food and Drug Administration. Priority Review. FDA. Accessed May 6, 2026.
Eli Lilly and Company. Zepbound Cost Information. Lilly Pricing Info. Accessed May 6, 2026.
Novo Nordisk. Wegovy Cost, Coverage, and Savings Information. Wegovy. Accessed May 6, 2026.
Kaiser E, Rohrer JS, Jensen D. Determination of residual trifluoroacetate in protein purification buffers and peptide preparations by ion chromatography. J Chromatogr A. 2004;1039(1-2):113-117. doi:10.1016/j.chroma.2004.03.044
Thermo Fisher Scientific. Determination of Trifluoroacetic Acid in Peptides. Thermo Fisher Scientific Application Note. Accessed May 6, 2026.
US Food and Drug Administration. Bacterial Endotoxins/Pyrogens. FDA. Published November 17, 2014. Accessed May 6, 2026.
US Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers. FDA Guidance for Industry. Updated March 18, 2026. Accessed May 6, 2026.
US Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. Updated September 16, 2025. Accessed May 6, 2026.
US Food and Drug Administration. Compounding When Drugs Are on FDA’s Drug Shortages List. FDA. Updated August 8, 2025. Accessed May 6, 2026.
US Food and Drug Administration. FDA’s Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. FDA. Accessed May 6, 2026.
Wilding JPH, Batterham RL, Davies M, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Suppl 1):A16-A17. doi:10.1210/jendso/bvab048.028
Sattar N, McGuire DK, Pavo I, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025. doi:10.1111/dom.16275
Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a post-hoc analysis of a phase 2 trial. Lancet Diabetes Endocrinol. 2025.